Drug Profile
Hydroxycarbamide - Addmedica
Alternative Names: Hydroxyurea - Addmedica; NSC-32065; Onco-carbide; Siklos; SQ-1089Latest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator ProStrakan
- Developer addmedica; Medunik USA
- Class Antianaemics; Antineoplastics; Small molecules; Urea compounds
- Mechanism of Action DNA synthesis inhibitors; Fetal haemoglobin stimulants; Nitric oxide stimulants; Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Sickle cell anaemia
Most Recent Events
- 28 Oct 2022 Addmedica completes a phase II trial in Sickle cell anaemia (In Children), in France (PO) (EudraCT2022-000168-22)
- 11 Mar 2022 Addmedica initiates a phase II trial in Sickle cell anaemia (In Children), in France (PO) (EudraCT2022-000168-22)
- 11 Mar 2022 Addmedica plans a phase II trial in Sickle cell anaemia (In Children), in France (PO) (EudraCT2022-000168-22)